News
Market and company headlines
AORTAll
Loading
11:00-17:00Oct 222 Stories
Artivion Announces Release Date and Teleconference Call Details for Third Quarter 2026 Financial Results
Artivion, Inc. (NYSE: AORT), a leading cardiac and vascular surgery company focused on aortic disease, announced today that third quarter 2026 financial results will be released on Thursday, November 5, 2026, after the market closes. On that day, the Company will hold a teleconference call and live webcast at 4:30 p.m. ET to discuss the results, followed by a question-and-answer session hosted by Pat Mackin, Chairman, President and Chief Executive Officer of Artivion.
Medical devices & supplies - cardiology, neurology, vascular stocks Q2 teardown: Artivion (NYSE:AORT) vs the rest
Earnings results often indicate what direction a company will take in the months ahead. With Q2 behind us, let’s have a look at Artivion (NYSE:AORT) and its peers.
10:00-12:00Oct 202 Stories
Artivion rises as Jefferies initiates at buy, sees ’attractive entry point’
Investing.com -- Artivion Inc (NYSE:AORT) shares gained 4.2% Tuesday after Jefferies initiated coverage on the cardiovascular medical device maker with a Buy rating and a $31 price target, framing the company as a compelling play on aortic surgery growth. The bullish call reflects optimism surrounding Artivion’s expanding product pipeline, which Wall Street expects to drive double-digit revenue expansion alongside expanding profit margins.
Artivion (AORT) Stock May Be 13% Undervalued On Cash Flow
Artivion has gone through a sharp reset in market expectations, with the share price down heavily over the past year yet still well ahead of where it was three years ago. That mix of long term gains and recent weakness puts the focus squarely on a single issue: whether the current price can be explained by the cash the business is expected to generate. Over the past 3 years the stock has gained 66.9%, which puts meaningful past returns on the line if the underlying cash flows do not support...